INCY
Incyte Corporation
Biotechnology · Healthcare · United States
116.80
close · 2026-10-29
value
68
cheaper than peers68
quality
98
stronger fundamentals98
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 4.07× | 79 |
| forward P/E | 13.41× | 66 |
| EV to EBITDA | 9.88× | 61 |
| price to book | 3.70× | 47 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.6% | 97 |
| operating margin | 41.9% | 96 |
| return on equity | 30.7% | 91 |
| revenue growth | 37.7% | 60 |
4 of 4 measures available
Facts
| market cap | $24B |
| free cash flow | $1.18B |
| employees | 2,844 |
| first trade | 1993-11-04 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 6.41 | 0.15 | 2.65 | 1.52 |
| free cash flow | $1.33B | $235.2M | $449.0M | $892.1M |
| net income | $1.29B | $32.6M | $597.6M | $340.7M |
| revenue | $5.14B | $4.24B | $3.70B | $3.39B |
| unusual items | $193.4M | $76.0M | $9.1M | -$99.7M |